Last $292.10 USD
Change Today -2.30 / -0.78%
Volume 263.0
RHHVF On Other Exchanges
Symbol
Exchange
OTC US
OTC US
Xetra
SIX Swiss Ex
Xetra
SIX Swiss Ex
Mexico
As of 10:49 AM 10/2/14 All times are local (Market data is delayed by at least 15 minutes).

roche holding ag-genusschein (RHHVF) Snapshot

Open
$292.86
Previous Close
$294.40
Day High
$292.86
Day Low
$291.50
52 Week High
02/24/14 - $340.18
52 Week Low
10/9/13 - $254.48
Market Cap
251.0B
Average Volume 10 Days
7.0K
EPS TTM
--
Shares Outstanding
702.6M
EX-Date
03/6/14
P/E TM
--
Dividend
$8.46
Dividend Yield
3.04%
Current Stock Chart for ROCHE HOLDING AG-GENUSSCHEIN (RHHVF)

roche holding ag-genusschein (RHHVF) Details

Roche Holding AG operates in the pharmaceuticals and diagnostics businesses in Switzerland, European Union, and internationally. It discovers, develops, and provides diagnostic and therapeutic products and services that enable patients and healthcare professionals in the detection, prevention, diagnosis, treatment, and treatment monitoring of diseases. The company provides pharmaceutical products for various therapeutic areas comprising oncology, virology, inflammation, metabolic disorders, and central nervous system. In addition, it offers a portfolio of diagnostics products, such as blood glucose meters for diabetes patients; point-of-care testing devices for use in doctors’ offices; high-throughput analyzers for hospitals and commercial diagnostic laboratories; and start-of-the-art instruments and reagents for life science research. The company has a collaboration agreement with Astrazeneca Plc to develop a plasma-based companion diagnostic test to support AZD9291, a drug candidate for treating non-small-cell lung cancer; and a collaboration agreement with AmorChem L.P. to discover novel small molecule disease-modifying therapy for the treatment of myotonic muscular dystrophy 1 or Steinert's disease. Roche Holding AG was founded in 1896 and is headquartered in Basel, Switzerland.

85,080 Employees
Last Reported Date: 01/30/14
Founded in 1896

roche holding ag-genusschein (RHHVF) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: SFr.5.1M
Compensation as of Fiscal Year 2013.

roche holding ag-genusschein (RHHVF) Key Developments

Roche Announces Final Survival Results from the Phase III CLEOPATRA Study

Roche announced final survival results from the Phase III CLEOPATRA study, which showed that adding Perjeta (pertuzumab) to Herceptin (trastuzumab) and docetaxel chemotherapy extended the lives (overall survival; OS) of people with previously untreated HER2-positive metastatic breast cancer (mBC) by 15.7 months compared to Herceptin and chemotherapy (median S: 56.5 vs. 40.8 months). No new safety signals were observed in the study. These data will be presented in the Presidential Symposium at the European Society for Medical Oncology (ESMO) 2014 congress in Madrid, Spain and are also featured in the official ESMO Press Briefing. Roche's Perjeta regimen extended the lives of people with an aggressive type of metastatic breast cancer by 15.7 months compared to Herceptin and chemotherapy Final data from Phase III CLEOPATRA study showed people with previously untreated HER2-positive metastatic breast cancer who received Perjeta, Herceptin and docetaxel chemotherapy lived a median of 56.5 months compared to 40.8 months for people who received Herceptin and hemotherapy Median overall survival of almost five years is the longest observed to date in people with this aggressive type of advanced breast cancer. Perjeta in combination with Herceptin and docetaxel chemotherapy is approved in the United States and the EU for people with previously untreated HER2-positive mBC. The Perjeta regimen has also been granted accelerated approval as a neoadjuvant treatment (use before surgery) for HER2-positive early breast cancer (eBC) by the U.S. Food and Drug Administration (FDA). An application to update the Marketing Authorisation to include this indication has also recently been submitted to the European Medicines Agency. CLEOPATRA (CLinical Evaluation Of Pertuzumab And TRAstuzumab) was an international, Phase III, randomised, double-blind, placebo-controlled study. The study compared the combination of Perjeta, Herceptin and docetaxel chemotherapy with placebo, Herceptin and chemotherapy in 808 people with previously untreated HER2-positive mBC, or with HER2-positive mBC that had come back after prior therapy in the adjuvant or neoadjuvant setting. The primary endpoint of the study was progression-free survival (PFS) as assessed by an independent review committee. Secondary endpoints included OS and safety profile. An interim OS analysis from the CLEOPATRA study was previously presented at the San Antonio Breast Cancer Symposium (SABCS) 2012. At the time of the analysis, median OS had not yet been reached for people receiving the Perjeta regimen as more than half of these people continued to survive. The results to be presented are from the final pre-specified OS analysis after a median follow-up of 50 months; median OS has now been reached for people receiving the Perjeta regimen. These data will be submitted to the regulatory authorities around the world for inclusion in the prescribing information for Perjeta. The safety profile of Perjeta in this analysis was consistent with that observed previously in the CLEOPATRA study, including Perjeta’s long-term cardiac safety. No new safety signals were observed, and the OS results of this final analysis were consistent across patient subgroups.

Roche Introduces New Fertility Test for Assessment of Ovarian Reserve for Pregnancy

Roche announced the launch of the Elecsys Anti-Müllerian Hormone (AMH) blood test, the first fully-automated AMH test for assessing a woman’s ovarian reserve. AMH is an important fertility marker used by healthcare professionals to assess ovarian reserve levels. The AMH blood test can be measured during any day of the menstrual cycle and is a superior indicator of ovarian reserve as compared to the follicle-stimulating hormone (FSH) and estradiol. In addition, the Elecsys AMH blood test produces standardized results for assessing ovarian reserve as compared with the use of ultrasound, in which the result is often dependent on the operator or clinic. The Elecsys AMH blood test will be available in all markets accepting the CE mark in Europe, Latin America, Middle East, Africa and Asia. The test is currently not available in the United States and Japan. In the future, the Elecsys AMH assay is also intended to be used in combination with the new human recombinant follicle-stimulating hormone (human rFSH) treatment currently in phase III development at Ferring Pharmaceuticals. This combination, which will make possible individualized dosing of human rFSH based on a woman’s specific AMH level, may provide an improved option for couples seeking to conceive through in vitro fertilization.

Roche Announces Availability of ACCU-CHEK(R) Aviva Expert system

Roche announced that Roche's ACCU-CHEK(R) Aviva Expert system, the first and only blood glucose meter system with a built-in insulin calculator to be approved by the U.S. Food and Drug Administration, is now available by prescription. The device represents a significant advancement in blood glucose meter technology for people with diabetes who take multiple daily insulin injections. The meter's integrated bolus calculator provides easy-to-use and reliable dose recommendations based on automated calculations, eliminating the need for manual dosing calculations and estimations. The ACCU-CHEK Aviva Expert system is indicated as an aid in the treatment of insulin-requiring diabetes. The ACCU-CHEK Aviva Expert system consists of the ACCU-CHEK Aviva Expert meter, ACCU-CHEK Aviva Plus test strips, ACCU-CHEK Aviva control solutions, and ACCU-CHEK Bolus Advisor feature. The ACCU-CHEK Aviva Expert system is intended to facilitate the optimization of glycemic control in patients who are trained in multiple daily insulin injection therapy and are under the supervision of healthcare professionals experienced in managing insulin-treated patients. The ACCU-CHEK Aviva Expert blood glucose monitoring system is intended to be used for the quantitative measurement of glucose in fresh capillary whole blood samples drawn from the fingertips. The ACCU-CHEK Aviva Expert blood glucose monitoring system is intended for self-testing outside the body (in vitro diagnostic use) by people with diabetes. The ACCU-CHEK Aviva Expert blood glucose monitoring system is intended to be used by a single person and should not be shared. The ACCU-CHEK Aviva Expert blood glucose monitoring system should not be used for the diagnosis or screening of diabetes or for neonatal use. Alternative site testing should NOT be used with the ACCU-CHEK Aviva Expert blood glucose monitoring system. The ACCU-CHEK Aviva Expert system is intended for prescription home use only. The ACCU-CHEK Aviva Expert meter is also indicated for the calculation of an insulin dose or carbohydrate intake based on user-entered data. The ACCU-CHEK Bolus Advisor, as a component of the ACCU-CHEK Aviva Expert meter, is intended for use in providing insulin dose recommendations in response to blood glucose, health events, and carbohydrate input. The ACCU-CHEK Bolus Advisor is intended to provide direction for insulin adjustment within the scope of a pre-planned treatment program from a healthcare professional. Before patient use, a healthcare professional must prescribe the ACCU-CHEK Aviva Expert system and provide the patient-specific target blood glucose, insulin-to-carbohydrate ratio, and insulin sensitivity parameters to be programmed into the ACCU-CHEK Bolus Advisor. Once programmed, a patient must consult with the healthcare professional before making any changes to these ACCU-CHEK Bolus Advisor settings.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RHHVF:US $292.10 USD -2.30

RHHVF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
General Electric Co $25.06 USD -0.10
Gilead Sciences Inc $104.65 USD -0.94
Merck & Co Inc $58.68 USD -0.035
Novartis AG SFr.89.50 CHF -0.30
Pfizer Inc $29.07 USD -0.08
View Industry Companies
 

Industry Analysis

RHHVF

Industry Average

Valuation RHHVF Industry Range
Price/Earnings 21.1x
Price/Sales 4.6x
Price/Book 12.8x
Price/Cash Flow 17.2x
TEV/Sales 3.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ROCHE HOLDING AG-GENUSSCHEIN, please visit www.roche.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.